EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sandoz Group AG's enterprise value is $17,228 Mil.
Sandoz Group AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $10,111 Mil. Therefore, Sandoz Group AG's EV-to-Revenue for today is 1.70.
The historical rank and industry rank for Sandoz Group AG's EV-to-Revenue or its related term are showing as below:
SDZXF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 1.64
SDZXF's EV-to-Revenue is ranked better than 61.09% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs SDZXF: 1.64
As of today (2024-09-24), Sandoz Group AG's stock price is $39.53.
Sandoz Group AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $23.46. Therefore, Sandoz Group AG's PS Ratio for today is 1.69.
Sandoz Group AG EV-to-Revenue Historical Data
The historical data trend for Sandoz Group AG's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sandoz Group AG EV-to-Revenue Chart
Sandoz Group AG Annual Data
Trend
Dec22
Dec23
EV-to-Revenue
-
1.74
Sandoz Group AG Semi-Annual Data
Dec22
Jun23
Dec23
Jun24
EV-to-Revenue
-
-
-
-
Competitive Comparison of Sandoz Group AG's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's EV-to-Revenue falls into.
Sandoz Group AG's current Enterprise Value is $17,228 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $10,111 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (OTCPK:SDZXF) EV-to-Revenue Explanation
Sandoz Group AG's share price for today is $39.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was $23.46.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Sandoz Group AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SDZXF has been successfully added to your